Ring Therapeutics

Ring Therapeutics, founded by Flagship Pioneering in 2017 and based in Cambridge, Massachusetts, is developing a novel class of gene delivery vectors called Anellovectors, derived from anelloviruses — ubiquitous, non-pathogenic commensal viruses found throughout the human virome. The company's platform unites vector-based technology capable of tissue and cellular tropism, payload versatility, and redosability with a scalable, modular manufacturing process, aiming to create programmable genetic medicines with broader therapeutic windows and reduced immune resistance than existing gene therapy vectors.